Hardware, Equipment & Parts
Compare Stocks
4 / 10Stock Comparison
MLAB vs NOVT vs MKSI vs TRMB
Revenue, margins, valuation, and 5-year total return — side by side.
Hardware, Equipment & Parts
Hardware, Equipment & Parts
Hardware, Equipment & Parts
MLAB vs NOVT vs MKSI vs TRMB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts | Hardware, Equipment & Parts |
| Market Cap | $586M | $4.86B | $20.25B | $14.65B |
| Revenue (TTM) | $248M | $981M | $4.07B | $3.69B |
| Net Income (TTM) | $4M | $54M | $327M | $456M |
| Gross Margin | 60.6% | 44.4% | 45.2% | 68.8% |
| Operating Margin | 7.0% | 11.9% | 14.8% | 17.7% |
| Forward P/E | 11.7x | 38.2x | 30.4x | 20.0x |
| Total Debt | $181M | $342M | $4.69B | $1.39B |
| Cash & Equiv. | $27M | $381M | $675M | $253M |
MLAB vs NOVT vs MKSI vs TRMB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Mesa Laboratories, … (MLAB) | 100 | 40.2 | -59.8% |
| Novanta Inc. (NOVT) | 100 | 132.7 | +32.7% |
| MKS Inc. (MKSI) | 100 | 284.8 | +184.8% |
| Trimble Inc. (TRMB) | 100 | 158.1 | +58.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MLAB vs NOVT vs MKSI vs TRMB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MLAB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.78, yield 0.6%
- Rev growth 11.5%, EPS growth 99.2%, 3Y rev CAGR 9.3%
- Beta 1.78, yield 0.6%, current ratio 0.63x
- 11.5% revenue growth vs TRMB's -2.6%
NOVT is the clearest fit if your priority is long-term compounding.
- 8.5% 10Y total return vs MKSI's 7.5%
MKSI is the clearest fit if your priority is momentum.
- +306.1% vs MLAB's -11.2%
TRMB is the #2 pick in this set and the best alternative if sleep-well-at-night and valuation efficiency is your priority.
- Lower volatility, beta 1.46, Low D/E 23.9%, current ratio 1.09x
- PEG 8.15 vs NOVT's 11.61
- 12.4% margin vs MLAB's 1.5%
- Beta 1.46 vs MKSI's 2.64, lower leverage
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.5% revenue growth vs TRMB's -2.6% | |
| Value | Lower P/E (11.7x vs 30.4x) | |
| Quality / Margins | 12.4% margin vs MLAB's 1.5% | |
| Stability / Safety | Beta 1.46 vs MKSI's 2.64, lower leverage | |
| Dividends | 0.6% yield, vs MKSI's 0.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +306.1% vs MLAB's -11.2% | |
| Efficiency (ROA) | 5.0% ROA vs MLAB's 0.9%, ROIC 6.8% vs 3.7% |
MLAB vs NOVT vs MKSI vs TRMB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MLAB vs NOVT vs MKSI vs TRMB — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MLAB leads in 2 of 6 categories
TRMB leads 1 • MKSI leads 1 • NOVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
TRMB leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MKSI is the larger business by revenue, generating $4.1B annually — 16.4x MLAB's $248M. TRMB is the more profitable business, keeping 12.4% of every revenue dollar as net income compared to MLAB's 1.5%. On growth, MKSI holds the edge at +15.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $248M | $981M | $4.1B | $3.7B |
| EBITDAEarnings before interest/tax | $37M | $179M | $945M | $785M |
| Net IncomeAfter-tax profit | $4M | $54M | $327M | $456M |
| Free Cash FlowCash after capex | $38M | $48M | $401M | $253M |
| Gross MarginGross profit ÷ Revenue | +60.6% | +44.4% | +45.2% | +68.8% |
| Operating MarginEBIT ÷ Revenue | +7.0% | +11.9% | +14.8% | +17.7% |
| Net MarginNet income ÷ Revenue | +1.5% | +5.5% | +8.0% | +12.4% |
| FCF MarginFCF ÷ Revenue | +15.2% | +4.9% | +9.8% | +6.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.6% | +8.5% | +15.2% | +11.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | -2.2% | +53.2% | +55.6% |
Valuation Metrics
MLAB leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 35.3x trailing earnings, TRMB trades at a 62% valuation discount to NOVT's 92.7x P/E. Adjusting for growth (PEG ratio), TRMB offers better value at 14.39x vs NOVT's 28.13x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $586M | $4.9B | $20.2B | $14.7B |
| Enterprise ValueMkt cap + debt − cash | $740M | $4.8B | $24.3B | $15.8B |
| Trailing P/EPrice ÷ TTM EPS | -294.78x | 92.71x | 68.83x | 35.34x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.71x | 38.25x | 30.36x | 20.01x |
| PEG RatioP/E ÷ EPS growth rate | — | 28.13x | — | 14.39x |
| EV / EBITDAEnterprise value multiple | 18.12x | 27.00x | 26.70x | 20.05x |
| Price / SalesMarket cap ÷ Revenue | 2.43x | 4.96x | 5.15x | 4.08x |
| Price / BookPrice ÷ Book value/share | 3.60x | 3.81x | 7.49x | 2.54x |
| Price / FCFMarket cap ÷ FCF | 13.86x | 100.38x | 40.74x | 110.00x |
Profitability & Efficiency
Evenly matched — NOVT and TRMB each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
MKSI delivers a 12.2% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $2 for MLAB. TRMB carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), MLAB scores 6/9 vs TRMB's 5/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.0% | +4.1% | +12.2% | +8.0% |
| ROA (TTM)Return on assets | +0.9% | +3.0% | +3.7% | +5.0% |
| ROICReturn on invested capital | +3.7% | +7.4% | +6.5% | +6.8% |
| ROCEReturn on capital employed | +4.9% | +8.3% | +7.2% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 6 | 5 |
| Debt / EquityFinancial leverage | 1.14x | 0.26x | 1.73x | 0.24x |
| Net DebtTotal debt minus cash | $154M | -$39M | $4.0B | $1.1B |
| Cash & Equiv.Liquid assets | $27M | $381M | $675M | $253M |
| Total DebtShort + long-term debt | $181M | $342M | $4.7B | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.36x | 4.89x | 2.84x | 12.26x |
Total Returns (Dividends Reinvested)
MKSI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MKSI five years ago would be worth $16,648 today (with dividends reinvested), compared to $4,350 for MLAB. Over the past 12 months, MKSI leads with a +306.1% total return vs MLAB's -11.2%. The 3-year compound annual growth rate (CAGR) favors MKSI at 54.1% vs MLAB's -12.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +33.8% | +22.6% | +78.8% | -21.0% |
| 1-Year ReturnPast 12 months | -11.2% | +14.6% | +306.1% | -6.7% |
| 3-Year ReturnCumulative with dividends | -33.0% | -15.2% | +266.0% | +30.1% |
| 5-Year ReturnCumulative with dividends | -56.5% | +5.7% | +66.5% | -22.0% |
| 10-Year ReturnCumulative with dividends | +4.5% | +853.7% | +750.6% | +166.8% |
| CAGR (3Y)Annualised 3-year return | -12.5% | -5.3% | +54.1% | +9.2% |
Risk & Volatility
Evenly matched — MKSI and TRMB each lead in 1 of 2 comparable metrics.
Risk & Volatility
TRMB is the less volatile stock with a 1.46 beta — it tends to amplify market swings less than MKSI's 2.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MKSI currently trades 92.0% from its 52-week high vs TRMB's 70.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 2.02x | 2.64x | 1.46x |
| 52-Week HighHighest price in past year | $131.20 | $149.95 | $326.83 | $87.50 |
| 52-Week LowLowest price in past year | $55.45 | $98.27 | $71.49 | $61.63 |
| % of 52W HighCurrent price vs 52-week peak | +80.9% | +90.9% | +92.0% | +70.7% |
| RSI (14)Momentum oscillator 0–100 | 66.1 | 62.6 | 65.3 | 36.8 |
| Avg Volume (50D)Average daily shares traded | 123K | 375K | 1.2M | 1.7M |
Analyst Outlook
MLAB leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: MLAB as "Hold", NOVT as "Buy", MKSI as "Buy", TRMB as "Buy". Consensus price targets imply 53.6% upside for TRMB (target: $95) vs -11.4% for MLAB (target: $94). For income investors, MLAB offers the higher dividend yield at 0.60% vs MKSI's 0.29%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $94.00 | $150.00 | $272.86 | $95.00 |
| # AnalystsCovering analysts | 8 | 3 | 29 | 28 |
| Dividend YieldAnnual dividend ÷ price | +0.6% | — | +0.3% | — |
| Dividend StreakConsecutive years of raises | 0 | — | 0 | — |
| Dividend / ShareAnnual DPS | $0.64 | — | $0.87 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.8% | +0.2% | +5.9% |
MLAB leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). TRMB leads in 1 (Income & Cash Flow). 2 tied.
MLAB vs NOVT vs MKSI vs TRMB: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MLAB or NOVT or MKSI or TRMB a better buy right now?
For growth investors, Mesa Laboratories, Inc.
(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus -2. 6% for Trimble Inc. (TRMB). Trimble Inc. (TRMB) offers the better valuation at 35. 3x trailing P/E (20. 0x forward), making it the more compelling value choice. Analysts rate Novanta Inc. (NOVT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MLAB or NOVT or MKSI or TRMB?
On trailing P/E, Trimble Inc.
(TRMB) is the cheapest at 35. 3x versus Novanta Inc. at 92. 7x. On forward P/E, Mesa Laboratories, Inc. is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Trimble Inc. wins at 8. 15x versus Novanta Inc. 's 11. 61x.
03Which is the better long-term investment — MLAB or NOVT or MKSI or TRMB?
Over the past 5 years, MKS Inc.
(MKSI) delivered a total return of +66. 5%, compared to -56. 5% for Mesa Laboratories, Inc. (MLAB). Over 10 years, the gap is even starker: NOVT returned +853. 7% versus MLAB's +4. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MLAB or NOVT or MKSI or TRMB?
By beta (market sensitivity over 5 years), Trimble Inc.
(TRMB) is the lower-risk stock at 1. 46β versus MKS Inc. 's 2. 64β — meaning MKSI is approximately 80% more volatile than TRMB relative to the S&P 500. On balance sheet safety, Trimble Inc. (TRMB) carries a lower debt/equity ratio of 24% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MLAB or NOVT or MKSI or TRMB?
By revenue growth (latest reported year), Mesa Laboratories, Inc.
(MLAB) is pulling ahead at 11. 5% versus -2. 6% for Trimble Inc. (TRMB). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -71. 3% for Trimble Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MLAB or NOVT or MKSI or TRMB?
Trimble Inc.
(TRMB) is the more profitable company, earning 11. 8% net margin versus -0. 8% for Mesa Laboratories, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRMB leads at 16. 9% versus 6. 8% for MLAB. At the gross margin level — before operating expenses — TRMB leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MLAB or NOVT or MKSI or TRMB more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Trimble Inc. (TRMB) is the more undervalued stock at a PEG of 8. 15x versus Novanta Inc. 's 11. 61x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Mesa Laboratories, Inc. (MLAB) trades at 11. 7x forward P/E versus 38. 2x for Novanta Inc. — 26. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRMB: 53. 6% to $95. 00.
08Which pays a better dividend — MLAB or NOVT or MKSI or TRMB?
In this comparison, MLAB (0.
6% yield), MKSI (0. 3% yield) pay a dividend. NOVT, TRMB do not pay a meaningful dividend and should not be held primarily for income.
09Is MLAB or NOVT or MKSI or TRMB better for a retirement portfolio?
For long-horizon retirement investors, Mesa Laboratories, Inc.
(MLAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield). MKS Inc. (MKSI) carries a higher beta of 2. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLAB: +4. 5%, MKSI: +750. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MLAB and NOVT and MKSI and TRMB?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
MLAB pays a dividend while NOVT, MKSI, TRMB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.